| Shantala Bindu, MD | |
|
4230 Burnham Ave, Las Vegas, NV 89119 | |
| (702) 733-7866 | |
| (702) 792-1319 |
| Full Name | Shantala Bindu |
|---|---|
| Gender | Female |
| Speciality | Pathology |
| Experience | 32 Years |
| Location | 4230 Burnham Ave, Las Vegas, Nevada |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306852975 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0101X | Pathology - Anatomic Pathology | 11103 (Nevada) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Rose Dominican Hospitals - Siena Campus | Henderson, NV | Hospital |
| Saint Rose Dominican Hospitals - San Martin Campus | Las vegas, NV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hoffman, Md, Associated Pathologists Chartered | 8224921861 | 14 |
News Archive
An insurer in Utah is encouraging consumers to use less medical care, but a study of California hospitals suggests that sometimes spending more really does improve patient outcomes.
Dyax Corp. announced today the publication of results from its second Phase 3, placebo-controlled trial, known as EDEMA4, evaluating KALBITOR (ecallantide) for the treatment of acute attacks of hereditary angioedema. The results, published in the June 2010 issue of the Annals of Allergy, Asthma, and Immunology, indicate that KALBITOR is effective in ameliorating HAE attacks, resolving associated symptoms and preventing attack progression.
The symptoms of appendicitis are often diffuse and it can be difficult to obtain an accurate diagnosis early in the course of the disease. It may be possible to predict the severity from a blood sample, and in this way determine the treatment on an individual basis. This is the conclusion of a thesis presented at the University of Gothenburg, sweden.
Cardium Therapeutics announced plans to report on preliminary safety and efficacy data from its Matrix Phase 2b Excellarate clinical study. Based on guidance from Cardium's independent clinical data management company which is currently completing the statistical analysis of all data for the Matrix clinical trial, Cardium expects to receive the locked unblinded data set and be in position to announce preliminary results on or before October 14, 2009.
› Verified 3 days ago
| Entity Name | Hoffman, Md, Associated Pathologists Chartered |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396810057 PECOS PAC ID: 8224921861 Enrollment ID: O20040206000042 |
News Archive
An insurer in Utah is encouraging consumers to use less medical care, but a study of California hospitals suggests that sometimes spending more really does improve patient outcomes.
Dyax Corp. announced today the publication of results from its second Phase 3, placebo-controlled trial, known as EDEMA4, evaluating KALBITOR (ecallantide) for the treatment of acute attacks of hereditary angioedema. The results, published in the June 2010 issue of the Annals of Allergy, Asthma, and Immunology, indicate that KALBITOR is effective in ameliorating HAE attacks, resolving associated symptoms and preventing attack progression.
The symptoms of appendicitis are often diffuse and it can be difficult to obtain an accurate diagnosis early in the course of the disease. It may be possible to predict the severity from a blood sample, and in this way determine the treatment on an individual basis. This is the conclusion of a thesis presented at the University of Gothenburg, sweden.
Cardium Therapeutics announced plans to report on preliminary safety and efficacy data from its Matrix Phase 2b Excellarate clinical study. Based on guidance from Cardium's independent clinical data management company which is currently completing the statistical analysis of all data for the Matrix clinical trial, Cardium expects to receive the locked unblinded data set and be in position to announce preliminary results on or before October 14, 2009.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Shantala Bindu, MD 4230 Burnham Avenue, Las Vegas, NV 89119 Ph: (702) 733-7866 | Shantala Bindu, MD 4230 Burnham Ave, Las Vegas, NV 89119 Ph: (702) 733-7866 |
News Archive
An insurer in Utah is encouraging consumers to use less medical care, but a study of California hospitals suggests that sometimes spending more really does improve patient outcomes.
Dyax Corp. announced today the publication of results from its second Phase 3, placebo-controlled trial, known as EDEMA4, evaluating KALBITOR (ecallantide) for the treatment of acute attacks of hereditary angioedema. The results, published in the June 2010 issue of the Annals of Allergy, Asthma, and Immunology, indicate that KALBITOR is effective in ameliorating HAE attacks, resolving associated symptoms and preventing attack progression.
The symptoms of appendicitis are often diffuse and it can be difficult to obtain an accurate diagnosis early in the course of the disease. It may be possible to predict the severity from a blood sample, and in this way determine the treatment on an individual basis. This is the conclusion of a thesis presented at the University of Gothenburg, sweden.
Cardium Therapeutics announced plans to report on preliminary safety and efficacy data from its Matrix Phase 2b Excellarate clinical study. Based on guidance from Cardium's independent clinical data management company which is currently completing the statistical analysis of all data for the Matrix clinical trial, Cardium expects to receive the locked unblinded data set and be in position to announce preliminary results on or before October 14, 2009.
› Verified 3 days ago
Mrs. June Durkee Sigman, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 7455 W Washington Ave Ste 301, Las Vegas, NV 89128 Phone: 877-562-5227 Fax: 702-732-2310 | |
Dr. Bert G. Dougherty, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 3059 S Maryland Pkwy, 100, Las Vegas, NV 89109 Phone: 702-732-3441 Fax: 702-732-2310 | |
Dr. David Patrick Marmaduke, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 3059 S Maryland Pkwy Ste 100, Las Vegas, NV 89109 Phone: 702-732-3441 Fax: 702-732-2310 | |
Narciss Mobini, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 4230 Burnham Ave, Las Vegas, NV 89119 Phone: 702-733-7866 Fax: 702-792-1319 | |
Mr. Jonathan Howard Hughes, MD PHD Pathology Medicare: Accepting Medicare Assignments Practice Location: 3059 S Maryland Pkwy Ste 100, Las Vegas, NV 89109 Phone: 702-732-3441 Fax: 702-732-2310 | |
Peter Aylward Scully, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 4230 Burnham Avenue, Las Vegas, NV 89119 Phone: 702-733-7866 Fax: 702-792-1319 | |
Jonathan Stuart Strauss, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 4230 Burnham Ave, Las Vegas, NV 89119 Phone: 702-733-7866 Fax: 702-792-1319 |